S&P 500   3,897.71 (-0.11%)
DOW   31,570.49 (+0.11%)
QQQ   321.38 (-0.68%)
AAPL   126.20 (-1.24%)
MSFT   234.21 (-1.15%)
FB   263.24 (-0.63%)
GOOGL   2,068.88 (-0.04%)
TSLA   704.50 (-1.94%)
AMZN   3,143.64 (-0.08%)
NVDA   547.28 (-1.15%)
BABA   240.11 (-0.65%)
CGC   35.92 (+3.43%)
GE   13.12 (+0.08%)
MU   93.64 (-1.18%)
NIO   45.64 (-8.28%)
AMD   85.64 (-0.87%)
T   28.25 (+0.57%)
F   12.18 (+1.67%)
ACB   11.66 (+5.62%)
DIS   195.50 (+0.27%)
BA   222.80 (-0.71%)
NFLX   550.66 (+0.00%)
BAC   35.71 (-0.22%)
S&P 500   3,897.71 (-0.11%)
DOW   31,570.49 (+0.11%)
QQQ   321.38 (-0.68%)
AAPL   126.20 (-1.24%)
MSFT   234.21 (-1.15%)
FB   263.24 (-0.63%)
GOOGL   2,068.88 (-0.04%)
TSLA   704.50 (-1.94%)
AMZN   3,143.64 (-0.08%)
NVDA   547.28 (-1.15%)
BABA   240.11 (-0.65%)
CGC   35.92 (+3.43%)
GE   13.12 (+0.08%)
MU   93.64 (-1.18%)
NIO   45.64 (-8.28%)
AMD   85.64 (-0.87%)
T   28.25 (+0.57%)
F   12.18 (+1.67%)
ACB   11.66 (+5.62%)
DIS   195.50 (+0.27%)
BA   222.80 (-0.71%)
NFLX   550.66 (+0.00%)
BAC   35.71 (-0.22%)
S&P 500   3,897.71 (-0.11%)
DOW   31,570.49 (+0.11%)
QQQ   321.38 (-0.68%)
AAPL   126.20 (-1.24%)
MSFT   234.21 (-1.15%)
FB   263.24 (-0.63%)
GOOGL   2,068.88 (-0.04%)
TSLA   704.50 (-1.94%)
AMZN   3,143.64 (-0.08%)
NVDA   547.28 (-1.15%)
BABA   240.11 (-0.65%)
CGC   35.92 (+3.43%)
GE   13.12 (+0.08%)
MU   93.64 (-1.18%)
NIO   45.64 (-8.28%)
AMD   85.64 (-0.87%)
T   28.25 (+0.57%)
F   12.18 (+1.67%)
ACB   11.66 (+5.62%)
DIS   195.50 (+0.27%)
BA   222.80 (-0.71%)
NFLX   550.66 (+0.00%)
BAC   35.71 (-0.22%)
S&P 500   3,897.71 (-0.11%)
DOW   31,570.49 (+0.11%)
QQQ   321.38 (-0.68%)
AAPL   126.20 (-1.24%)
MSFT   234.21 (-1.15%)
FB   263.24 (-0.63%)
GOOGL   2,068.88 (-0.04%)
TSLA   704.50 (-1.94%)
AMZN   3,143.64 (-0.08%)
NVDA   547.28 (-1.15%)
BABA   240.11 (-0.65%)
CGC   35.92 (+3.43%)
GE   13.12 (+0.08%)
MU   93.64 (-1.18%)
NIO   45.64 (-8.28%)
AMD   85.64 (-0.87%)
T   28.25 (+0.57%)
F   12.18 (+1.67%)
ACB   11.66 (+5.62%)
DIS   195.50 (+0.27%)
BA   222.80 (-0.71%)
NFLX   550.66 (+0.00%)
BAC   35.71 (-0.22%)
Log in
NYSE:ZTS

Zoetis Stock Forecast, Price & News

$157.21
-0.48 (-0.30 %)
(As of 03/2/2021 09:50 AM ET)
Add
Compare
Today's Range
$157.06
Now: $157.21
$158.85
50-Day Range
$153.15
MA: $160.94
$169.39
52-Week Range
$90.14
Now: $157.21
$176.64
Volume2,720 shs
Average Volume1.94 million shs
Market Capitalization$74.70 billion
P/E Ratio46.65
Dividend Yield0.64%
Beta0.71
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Zoetis logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP98978V10
Phone973-822-7000
Employees10,600
Year Founded2012

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.26 billion
Cash Flow$4.47 per share
Book Value$5.69 per share

Profitability

Net Income$1.50 billion

Miscellaneous

Market Cap$74.70 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

2.14 out of 5 stars

Medical Sector

36th out of 1,966 stocks

Pharmaceutical Preparations Industry

12th out of 772 stocks

Analyst Opinion: 1.3Community Rank: 3.2Dividend Strength: 1.7Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -
$157.21
-0.48 (-0.30 %)
(As of 03/2/2021 09:50 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zoetis (NYSE:ZTS) Frequently Asked Questions

Is Zoetis a buy right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There are currently 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zoetis stock.
View analyst ratings for Zoetis
or view top-rated stocks.

What stocks does MarketBeat like better than Zoetis?

Wall Street analysts have given Zoetis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zoetis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Zoetis?

Zoetis saw a increase in short interest during the month of January. As of January 29th, there was short interest totaling 3,690,000 shares, an increase of 34.2% from the January 14th total of 2,750,000 shares. Based on an average daily volume of 1,730,000 shares, the days-to-cover ratio is currently 2.1 days. Approximately 0.8% of the company's shares are sold short.
View Zoetis' Short Interest
.

When is Zoetis' next earnings date?

Zoetis is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Zoetis
.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) issued its quarterly earnings data on Tuesday, February, 16th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.86 by $0.05. Zoetis had a net margin of 25.50% and a trailing twelve-month return on equity of 63.89%. During the same quarter in the previous year, the firm earned $0.92 EPS.
View Zoetis' earnings history
.

How has Zoetis' stock price been impacted by COVID-19?

Zoetis' stock was trading at $130.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZTS stock has increased by 20.7% and is now trading at $157.21.
View which stocks have been most impacted by COVID-19
.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis declared a quarterly dividend on Wednesday, February 10th. Shareholders of record on Wednesday, April 21st will be paid a dividend of $0.25 per share on Tuesday, June 1st. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date of this dividend is Tuesday, April 20th.
View Zoetis' dividend history
.

Is Zoetis a good dividend stock?

Zoetis pays an annual dividend of $1.00 per share and currently has a dividend yield of 0.64%. Zoetis does not yet have a strock track record of dividend growth. The dividend payout ratio of Zoetis is 27.47%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Zoetis will have a dividend payout ratio of 24.27% next year. This indicates that Zoetis will be able to sustain or increase its dividend.
View Zoetis' dividend history.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis updated its FY 2021 Pre-Market earnings guidance on Tuesday, February, 16th. The company provided earnings per share (EPS) guidance of 4.36-4.46 for the period, compared to the Thomson Reuters consensus estimate of $4.26. The company issued revenue guidance of $7.4-7.55 billion, compared to the consensus revenue estimate of $7.11 billion.

What price target have analysts set for ZTS?

14 Wall Street analysts have issued 1-year price objectives for Zoetis' stock. Their forecasts range from $126.00 to $203.00. On average, they expect Zoetis' share price to reach $167.73 in the next year. This suggests a possible upside of 6.7% from the stock's current price.
View analysts' price targets for Zoetis
or view top-rated stocks among Wall Street analysts.

Who are Zoetis' key executives?

Zoetis' management team includes the following people:
  • Ms. Kristin C. Peck, CEO & Director (Age 50, Pay $1.53M)
  • Mr. Glenn C. David, Exec. VP & CFO (Age 49, Pay $1.52M)
  • Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 60, Pay $1.51M)
  • Ms. Roxanne Lagano, Exec. VP and Chief HR Officer & Global Operations (Age 56)
  • Ms. Wafaa Mamilli, Exec. VP and Chief Information & Digital Officer (Age 54)
  • Mr. Steven Frank, VP of Investor Relations
  • Ms. Heidi C. Chen, Exec. VP, Gen. Counsel & Corp. Sec. (Age 54)
  • Mr. William Price, VP & Chief Communications Officer
  • Mr. Roman Trawicki, Exec. VP and Pres of Global Manufacturing & Supply (Age 57)
  • Mr. Timothy J. Bettington, Exec. VP & Pres of U.S. Operations (Age 47)

What is Kristin Peck's approval rating as Zoetis' CEO?

47 employees have rated Zoetis CEO Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 84% among Zoetis' employees. 72.0% of employees surveyed would recommend working at Zoetis to a friend.

Who are some of Zoetis' key competitors?

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil Co. (ATH.TO) (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Who are Zoetis' major shareholders?

Zoetis' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.57%), Alliancebernstein L.P. (3.50%), FMR LLC (2.95%), Price T Rowe Associates Inc. MD (1.93%), Clearbridge Investments LLC (1.81%) and Morgan Stanley (1.70%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Robert W Scully, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends for Zoetis
.

Which institutional investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including Sonora Investment Management LLC, Janus Henderson Group PLC, Amundi Pioneer Asset Management Inc., UBS Asset Management Americas Inc., Nuveen Asset Management LLC, Morgan Stanley, Renaissance Technologies LLC, and DSM Capital Partners LLC. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Roman Trawicki, Roxanne Lagano, and Willie M Reed.
View insider buying and selling activity for Zoetis
or view top insider-selling stocks.

Which institutional investors are buying Zoetis stock?

ZTS stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Alliancebernstein L.P., BlackRock Inc., Lazard Freres Gestion S.A.S., Robeco Institutional Asset Management B.V., TCW Group Inc., Manning & Napier Group LLC, and Intermede Investment Partners Ltd.
View insider buying and selling activity for Zoetis
or or view top insider-buying stocks.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $157.21.

How much money does Zoetis make?

Zoetis has a market capitalization of $74.70 billion and generates $6.26 billion in revenue each year. The company earns $1.50 billion in net income (profit) each year or $3.64 on an earnings per share basis.

How many employees does Zoetis have?

Zoetis employs 10,600 workers across the globe.

When was Zoetis founded?

Zoetis was founded in 2012.

What is Zoetis' official website?

The official website for Zoetis is www.zoetis.com.

Where are Zoetis' headquarters?

Zoetis is headquartered at 10 Sylvan Way, Parsippany NJ, 07054.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.